Yousefzadeh, M. (2024). INVESTIGATION OF TRANSCRIPTIONAL CHANGES IN IMMUNE CELL POPULATIONS OF MICE TREATED WITH RAPAMYCIN. Innovation in Aging, 8(Supplement_1), 396–396. https://doi.org/10.1093/geroni/igae098.1289

Saha, N., Lee, S. G., Brockmann, E.-C., de la Cruz, M. J., Goldgur, Y., Mendoza, R. P., Stanchina, E. de, Love, T. M., Marvald, J., Xu, Y., Xu, K., Himanen, J. P., Lamminmäki, U., Veach, D., & Nikolov, D. B. (2024). Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells. Biomedicine & Pharmacotherapy, 180, 117605. https://doi.org/10.1016/j.biopha.2024.117605

Zhong, J., Lerrer, S., & Mor, A. (2024). An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies. BIO-PROTOCOL, 14(1352). https://doi.org/10.21769/bioprotoc.5057

Fleischer, S., Nash, T. R., Tamargo, M. A., Lock, R. I., Venturini, G., Morsink, M., Graney, P. L., Li, V., Lamberti, M. J., Liberman, M., Kim, Y., Tavakol, D. N., Zhuang, R. Z., Whitehead, J., Friedman, R. A., Soni, R. K., Seidman, J. G., Seidman, C. E., Geraldino-Pardilla, L., … Vunjak-Novakovic, G. (2024). An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury. Nature Cardiovascular Research, 3(9), 1123–1139. https://doi.org/10.1038/s44161-024-00525-w

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008

Askanase, A. D., Furie, R. A., Dall’Era, M., Bomback, A. S., Schwarting, A., Zhao, M.-H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., van Vollenhoven, R., & Urowitz, M. B. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine, 11(1), e001124. https://doi.org/10.1136/lupus-2023-001124

Mayer, B. T., Zhang, L., deCamp, A. C., Yu, C., Sato, A., Angier, H., Seaton, K. E., Yates, N., Ledgerwood, J. E., Mayer, K., Caskey, M., Nussenzweig, M., Stephenson, K., Julg, B., Barouch, D. H., Sobieszczyk, M. E., Edupuganti, S., Kelley, C. F., McElrath, M. J., … Huang, Y. (2024). Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics, 16(5), 594. https://doi.org/10.3390/pharmaceutics16050594

Krustev, E., Hanly, J. G., Chin, R., Buhler, K. A., Urowitz, M. B., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sánchez-Guerrero, J., Bernatsky, S., Wallace, D. J., Isenberg, D., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M. A., Ginzler, E. M., … Choi, M. Y. (2024). Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus. Lupus Science & Medicine, 11(1), e001139. https://doi.org/10.1136/lupus-2023-001139

Cherng, H.-J. J., & Herrera, A. (2024). Now You “CD20,” Now You Don’t: A Vanishing Act in B-cell Lymphomas After Bispecific Antibody Treatment. The Hematologist, 21(2). https://doi.org/10.1182/hem.v21.2.202425

Winter, H., Baldassano, R. N., Pfeffkorn, M. D., Wali, P., Verstraete, S. G., Picoraro, J. A., Washek, M. A., Kumar, N., Mortan, W., Havard- Jr, M., Blystone, L., Trombler, B., Pursley, C., Lin, X., Dillon, S. T., Gu, X., Otu, H. H., Ngo, L., & Libermann, T. A. (2024). P192 Personalizing treatment for predicting response to infliximab in children with Crohn’s disease using proteomic biomarkers. Journal of Crohn’s and Colitis, 18(Supplement_1), i506–i506. https://doi.org/10.1093/ecco-jcc/jjad212.0322

Mohan, M., Shah, N., Luan, D., Monge, J., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., Zangari, M., Al Hadidi, S., Cooper, D. L., Lentzsch, S., van Rhee, F., D’Souza, A., Szabo, A., … Chakraborty, R. (2023). Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood, 142(Supplement 1), 545–545. https://doi.org/10.1182/blood-2023-174875

Diefenbach, C. S., Jegede, O., Ansell, S. M., Steidl, C., Natkunam, Y., Scott, D. W., Mehta-Shah, N., Amengual, J. E., Forlenza, C. J., Cole, P. D., Bartlett, N. L., David, K. A., Advani, R. H., Ambinder, R. F., Thomas, S., Ibrahimi, S., & Kahl, B. S. (2023). Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412). Blood, 142(Supplement 1), 607–607. https://doi.org/10.1182/blood-2023-184531

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., Maly, J. J., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Bumma, N. (2023). Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood, 142(Supplement 1), 4746–4746. https://doi.org/10.1182/blood-2023-177968

Liu, J., O’Malley, D., Nieuwenhuysen, E. V., Moore, K., Hamilton, E., Yeku, O., Bouberhan, S., Hou, J., Schröder, D., Wang, B., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Lowy, I., Uldrick, T., Miller, E., & O’Cearbhaill, R. (2023). PO011LBA/#1512  Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results. Plenary 03: Oral Abstract Presentations – Ovarian Cancer. https://doi.org/10.1136/ijgc-2023-igcs.11

O’Cearbhaill, R. E., Moore, K. N., Yeku, O., Liu, J. F., Bouberhan, S., Hamilton, E. P., Hou, J. Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T. S., Miller, E. A., & O’Malley, D. (2023). 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Annals of Oncology, 34, S516–S517. https://doi.org/10.1016/j.annonc.2023.09.1933

Schreidah, C. M., Reynolds, G. B., Fahmy, L. M., Carvajal, R. D., Vermeer, M. H., Whittaker, S., Pe’er, I., & Geskin, L. J. (2023). Scoping review of genetic databases for rare dermatologic diseases: Opportunity for artificial intelligence and machine learning. JAAD International, 12, 24–31. https://doi.org/10.1016/j.jdin.2023.02.017

Sergeeva, A. P., Katsamba, P. S., Liao, J., Sampson, J. M., Bahna, F., Mannepalli, S., Morano, N. C., Shapiro, L., Friesner, R. A., & Honig, B. (2023). Free Energy Perturbation Calculations of Mutation Effects on SARS-CoV-2 RBD::ACE2 Binding Affinity. Journal of Molecular Biology, 435(15), 168187. https://doi.org/10.1016/j.jmb.2023.168187

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110

Askanase, A., Stach, C., Brittain, C., Stojan, G., & Furie, R. (2023). POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.1991

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). POS1153 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3052

Askanase, A., Furie, R., Dall’era, M., Bomback, A., Schwarting, A., Zhao, M. H., Bruce, I. N., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R., Van Vollenhoven, R., & Urowitz, M. B. (2023). AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.3897

Hamid, O., Lewis, K., Weise, A., McKean, M., Papadopoulos, K. P., Crown, J., Kim, T. M., Lakhani, N. J., Kaczmar, J., Kudchadkar, R., Spira, A., Rabinowits, G., Kim, K., Carvajal, R., Williamson, S., Ioffe, E., Chen, S., Mani, J., Jankovic, V., … Gullo, G. (2023). Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine, 7(2), s179. https://doi.org/10.25251/skin.7.supp.179

Askanase, A., Furie, R., DallEra, M., Bomback, A., Schwarting, A., Zhao, M.-H., Bruce, I., Khamashta, M., Rubin, B., Carroll, A., Daniels, M., Levy, R. A., Vollenhoven, R. van, Urowitz, M., & David, N. (2023). APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE. Congresso Brasileiro de Reumatologia, 1. https://doi.org/10.47660/cbr.2023.2501

Strazza, M., Moore, E. K., Adam, K., Azoulay-Alfaguter, I., & Mor, A. (2022). Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth. Molecular Therapy - Methods & Clinical Development, 27, 380–390. https://doi.org/10.1016/j.omtm.2022.10.012

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772

Friedman, C., Carvajal, R., Davar, D., Castanon, E., Ascierto, P., Calvo, E., O’Hara, M., Powell, S., Shapira-Frommer, R., Garralda, E., Renouf, D. J., Perets, R., Yunan, M., Ravindran, P., Hammell, A., O’Brien, S., Xu, K., Wilson, N., Jhatakia, A., … Gutierrez, M. (2022). 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results. Regular and Young Investigator Award Abstracts, A620–A621. https://doi.org/10.1136/jitc-2022-sitc2022.0592

Qiu, A., Miller, A., Zotti, F. D., Santhanakrishnan, M., Hendrickson, J. E., Tredicine, M., Stowell, S. R., Luckey, C. J., Zimring, J. C., & Hudson, K. E. (2022). FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.972723

Van Nieuwenhuysen, E., O’Malley, D., O’Cearbhaill, R. E., Moore, K. N., Hamilton, E. P., Yeku, O., Bouberhan, S., Hou, J. Y., Yoo, S.-Y., Brouwer-Visser, J., Cheung, H. K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T. S., Miller, E. A., & Liu, J. F. (2022). 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis. Annals of Oncology, 33, S784. https://doi.org/10.1016/j.annonc.2022.07.651

Hamid, O., Sato, T., Davar, D., Callahan, M. K., Thistlethwaite, F., Aljumaily, R., Johnson, M. L., Arkenau, H.-T., Ileana Dumbrava, E. E., Izar, B., Chen, H. A., Marshall, S., Yuan, Y., Deo, M., Stanhope, S., Collins, L., Mundy, R., Abdullah, S. E., & Lopez, J. S. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology, 33, S875. https://doi.org/10.1016/j.annonc.2022.07.854

Kyi, C. K., Spira, A., Carbone, D. P., Johnson, M. L., Henick, B. S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J. R., Catenacci, D., Liao, C.-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A. R., & Goldman, J. W. (2022). 736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). Annals of Oncology, 33, S880. https://doi.org/10.1016/j.annonc.2022.07.862

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 6, 90–91. https://doi.org/10.1097/01.hs9.0000843648.44771.79

Petri, M. A., Bertsias, G., Daniels, M., Fox, N. L., Hahn, B. H., Hammer, A., Harris, J., Quasny, H., Tani, C., & Askanase, A. (2022). POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases, 81, 323. https://doi.org/10.1136/annrheumdis-2022-eular.1807